AUSTIN, Texas, April 26 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. announced today that a patent has been awarded by the U.S. Patent and Trademark Office which broadly covers methods used to produce adenoviral p53, thus expanding Introgen’s adenoviral p53 portfolio and protection for its lead cancer therapy, ADVEXIN. The patent, U.S. Patent No. 7,033,750, is one of numerous patents, pending or issued, that Introgen has licensed exclusively from the Board of Regents of The University of Texas System which cover its therapies.
Introgen’s ADVEXIN therapy uses non-replicating adenovirus, a very important and frequently used tool in the fields of tumor suppressor therapy and vaccines. In addition to Introgen’s product candidates ADVEXIN, INGN 241, INGN 225, INGN 224 and INGN 007, there are a number of purified adenoviral products being developed worldwide.
“This patent adds considerably to Introgen’s extensive adenovirus intellectual property portfolio,” said David L. Parker, J.D., Ph.D., vice president of Intellectual Property for Introgen. “This patent is of particular importance in that it is directed to the production of adenoviral p53 in producer cells, and complements our existing U.S. portfolio, which includes patents directed to pharmaceutical compositions of adenoviral p53, the adenoviral p53 itself and to clinical applications of adenoviral p53.”
Introgen holds a license agreement with The University of Texas M. D. Anderson Cancer Center to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas Board of Regents owns stock in Introgen. These arrangements are managed in accordance with M.D. Anderson’s conflict of interest policies.
About ADVEXIN
ADVEXIN p53 therapy is a targeted molecular therapy with broad applicability in a wide range of tumor types and clinical settings because it targets one of the most fundamental and common molecular defects, abnormal p53 tumor suppressor function, associated with cancer initiation, progression and treatment resistance.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be “forward-looking” statements, including but are not limited to those relating to Introgen’s intellectual property portfolio. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene- based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: http://www.introgen.com .
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke@introgen.com
Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc., +1-512-708-9310Ext. 322, or c.burke@introgen.com
Web site: http://www.introgen.com/
